About Immtech InternationalImmtech International, is a pharmaceutical company developing and commercializing oral drugs against infectious diseases and neoplastic and metabolic to treat. We are developing treatments for fungal infections, malaria, tuberculosis, diabetes, Pneumocystis pneumonia, and tropical diseases, including African sleeping sickness and leishmaniasis. We have an exclusive worldwide license to a dicationic pharmaceutical platform from which is developing a pipeline of products to large, global markets can commercialize tapped generic levitra reviews . Uncertainties.c pharmaceutical platform that includes DB289, was developed by a consortium of scientists led by researchers at the University of North Carolina at Chapel Hill and Georgia State University. Safe Harbor Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech International ‘s business which forward-looking statements fact, constitute forward-looking statements that involve risks and uncertainties. For a discussion of such risks and uncertainties that could cause actual results to differ materially from forward-looking statements forward-looking statements, see Risk Factors in the Company’s Annual Report on Form 10 – K for the recently completed fiscal year.
‘. Time is not a luxury that can provide people with Parkinson’s disease, ‘said Rees Jenkins, a North Carolina patient advocate. ‘Delaying access to promising new therapies can be the difference between life and death for many patients. Starting human clinical trials on GDNF. Do what is right. (more…)